Bradley Foster & Sargent Inc. CT Sells 21,222 Shares of Zoetis Inc. $ZTS

Bradley Foster & Sargent Inc. CT decreased its position in Zoetis Inc. (NYSE:ZTS) by 13.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 138,622 shares of the company’s stock after selling 21,222 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Zoetis were worth $16,387,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Lombard Odier Asset Management Switzerland SA raised its holdings in Zoetis by 2.6% in the 1st quarter. Lombard Odier Asset Management Switzerland SA now owns 16,482 shares of the company’s stock worth $1,948,000 after acquiring an additional 412 shares during the period. Lombard Odier Asset Management Europe Ltd grew its position in shares of Zoetis by 33.3% in the first quarter. Lombard Odier Asset Management Europe Ltd now owns 93,097 shares of the company’s stock valued at $11,005,000 after purchasing an additional 23,239 shares during the last quarter. Waverly Advisors LLC grew its position in shares of Zoetis by 19.6% in the first quarter. Waverly Advisors LLC now owns 12,421 shares of the company’s stock valued at $1,468,000 after purchasing an additional 2,036 shares during the last quarter. Wealth Alliance LLC increased its stake in shares of Zoetis by 24.7% in the first quarter. Wealth Alliance LLC now owns 12,456 shares of the company’s stock worth $1,472,000 after purchasing an additional 2,465 shares during the period. Finally, Cumberland Partners Ltd bought a new position in shares of Zoetis in the first quarter worth about $1,052,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of ZTS stock opened at $75.32 on Friday. The stock’s fifty day simple moving average is $77.29 and its 200 day simple moving average is $104.25. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48. The firm has a market cap of $31.58 billion, a price-to-earnings ratio of 12.49, a P/E/G ratio of 1.18 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts expect that Zoetis Inc. will post 6.87 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. JPMorgan Chase & Co. cut their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Stifel Nicolaus reduced their price target on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $119.50.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Several firms announced or promoted securities-fraud litigation against Zoetis, which can weigh on sentiment by raising legal, financial, and reputational risk for the company. Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: The class-action deadline reminders may keep the controversy in the spotlight and encourage more shareholder claims, adding overhang to the stock. ZOETIS CLASS ACTION DEADLINE MONDAY JULY 27th
• Neutral Sentiment: One Seeking Alpha commentary argues Zoetis sentiment remains strong and fundamentals are improving, offering a more constructive longer-term view. Zoetis: Sentiment Keeps Winning As Fundamentals Improve

Insider Activity

In other news, Director Michael B. Mccallister bought 3,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. The trade was a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares of the company’s stock, valued at $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.